The potential of medical abortion to reduce maternal mortality in Africa: What benefits for Tanzania and Ethiopia?

PLoS ONE

Volumn 5, Issue 10, 2010, Pages

  Baggaley, Rebecca F ^a   Burgin, Joanna ^b   Campbell, Oona M R ^c  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b MARIE STOPES INTERNATIONAL   (United Kingdom)

^c LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

MISOPROSTOL; ABORTIVE AGENT;

ARTICLE; BIRTH RATE; DECISION TREE; DRUG COST; ETHIOPIA; HEALTH CARE ACCESS; HEALTH CARE AVAILABILITY; HEALTH CARE POLICY; HUMAN; INDUCED ABORTION; MATERNAL ATTITUDE; MATERNAL MORTALITY; MEDICAL ABORTION; RISK ASSESSMENT; TANZANIA; UNWANTED PREGNANCY; FEMALE; PREGNANCY;

ABORTIFACIENT AGENTS, NONSTEROIDAL; ABORTION, INDUCED; ETHIOPIA; FEMALE; HUMANS; MATERNAL MORTALITY; MISOPROSTOL; PREGNANCY; TANZANIA;

EID: 78149427826     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0013260     Document Type: Article

References (58)

1. United Nations Website: Millennium Development Goals. Available: http://www.un.org/millenniumgoals/ Accessed 2007 August 20.
2. World Health Organisation (2004) Unsafe Abortion: Global and Regional Estimates of the Incidence of Unsafe Abortion and Associated Mortality in 2000, 4th Edition. World Health Organisation, Geneva, Switzerland. Available http://whqlibdoc.who.int/publications/2004/9241591803.pdf Accessed 2009 Sep 12.
3. World Bank (2007) HNP Discussion Paper. Population Issues in the 21st Century: The Role of the World Bank. Available: http://siteresources.worldbank.org/HEALTHNUTRITIONANDPOPULATION/Resource s/281627-1095698140167/PopulationDiscussionPaperApril07Final.pdf. Accessed 2009 July 31.
4. Grimes DA, Benson J, Singh S, Romero M, Ganatra B, et al. (2006) Unsafe abortion: the preventable pandemic. Lancet 368: 1908-1919.
5. United Nations. The Millennium Development Goals Report. New York 2008. Available at: http://www.un.org/millenniumgoals/ (accessed 13th May 2009).
6. Khan KS, Wojdyla D, Say L, Gulmezoglu AM, Van Look PF (2006) WHO analysis of causes of maternal death: a systematic review. Lancet 367: 1066-1074.
7. Warriner I. 'Unsafe Abortion: An Overview of Priorities and Needs'. In Preventing Unsafe abortion and its Consequences: Priorities for Research and Action, New York, AGI, 2006, 2 p.
8. The Alan Guttmacher Institute (1999) Sharing Responsibility: Women, Society and Abortion Worldwide. New York. Available: http://www.guttmacher.org/pubs/sharing.pdf Accessed 2009 February 26. 26 p.
9. Henshaw SK, Singh S, Haas T (1999) The incidence of abortion worldwide. Int Fam Plann Persp 25: S30-38.
10. Creinin MD (2000) Medical abortion regimens: historical context and overview. Am J Obstet Gynecol 183: S3-9.
11. Grossman D, Blanchard K, Blumenthal P (2008) Complications after second trimester surgical and medical abortion. Reprod Health Matters 16: 173-182.
12. Willmott FJ, Scherf C, Ford SM, Lim K (2008) Rupture of uterus in the first trimester during medical termination of pregnancy for exomphalos using mifepristone/misoprostol. BJOG 115: 1575-1577.
13. Goyal V (2009) Uterine rupture in second-trimester misoprostol-induced abortion after cesarean delivery: a systematic review. Obstet Gynecol 113: 1117-1123.
14. Majoko F, Magwali T, Zwizwai M (2002) Uterine rupture associated with use of misoprostol for induction of labor. Int J Gynaecol Obstet 76: 77-78.
15. Kahn JG, Becker BJ, MacIsaa L, Amory JK, Neuhaus J, et al. (2000) The efficacy of medical abortion: a meta-analysis. Contraception 61: 29-40.
16. von Hertzen H, Piaggio G, Huong NT, Arustamyan K, Cabezas E, et al. (2007) Efficacy of two intervals and two routes of administration of misoprostol for termination of early pregnancy: a randomised controlled equivalence trial. Lancet 369: 1938-1946.
17. Bhattacharjee N, Saha SP, Ghoshroy SC, Bhowmik S, Barui G (2008) A randomised comparative study on sublingual versus vaginal administration of misoprostol for termination of pregnancy between 13 to 20 weeks. Aust N Z J Obstet Gynaecol 48: 165-171.
18. Carbonell JL, Rodriguez J, Aragon S, Velazco A, Tanda R, et al. (2001) Vaginal misoprostol 1000 microg for early abortion. Contraception 63: 131-136.
19. Carbonell JL, Varela L, Velazco A, Fernandez C (1997) The use of misoprostol for termination of early pregnancy. Contraception 55: 165-168.
20. Coyaji K, Elul B, Krishna U, Otiv S, Ambardekar S, et al. (2002) Mifepristonemisoprostol abortion: a trial in rural and urban Maharashtra, India. Contraception 66: 33-40.
21. Hajri S (2004) Medical abortion: the Tunisian experience. Afr J Reprod Health 8: 63-69.
22. Hamoda H, Ashok PW, Flett GM, Templeton A (2005) Medical abortion at 9-13 weeks' gestation: a review of 1076 consecutive cases. Contraception 71: 327-332.
23. Kapp N, Borgatta L, Stubblefield P, Vragovic O, Moreno N (2007) Mifepristone in second-trimester medical abortion: a randomized controlled trial. Obstet Gynecol 110: 1304-1310.
24. Mundle S, Elul B, Anand A, Kalyanwala S, Ughade S (2007) Increasing access to safe abortion services in rural India: experiences with medical abortion in a primary health center. Contraception 76: 66-70.
25. Thi Nhu Ngoc N, Winikoff B, Clark S, Ellertson C, Ngoc Am K, et al. (1999) Safety, Efficacy and Acceptability of Mifepristone-Misoprostol Medical Abortion in Vietnam. International Family Planning Perspectives 25: 10-14 & 33.
26. Winikoff B, Sivin I, Coyaji KJ, Cabezas E, Bilian X, et al. (1997) The Acceptability of Medical Abortion in China, Cuba, and India. International Family Planning Perspectives 23: 73-78 & 89.
27. Miller S, Lehman T, Campbell M, Hemmerling A, Anderson SB, et al. (2005) Misoprostol and declining abortion-related morbidity in Santo Domingo, Dominican Republic: a temporal association. BJOG 112: 1291-1296.
28. Barbosa RM, Arilha M (1993) The Brazilian experience with Cytotec. Stud Fam Plann 24: 236-240.
29. Berer M (2005) Medical abortion: a fact sheet. Reprod Health Matters 13: 20-24.
30. Costa SH, Vessey MP (1993) Misoprostol and illegal abortion in Rio de Janeiro, Brazil. Lancet 341: 1258-1261.
31. Harper CC, Blanchard K, Grossman D, Henderson JT, Darney PD (2007) Reducing maternal mortality due to elective abortion: Potential impact of misoprostol in low-resource settings. Int J Gynaecol Obstet 98: 66-69.
32. Prata N, Sreenivas A, Vahidnia F, Potts M (2009) Saving maternal lives in resource-poor settings: facing reality. Health Policy 89: 131-148.
33. Hu D, Bertozzi SM, Gakidou E, Sweet S, Goldie SJ (2007) The costs, benefits, and cost-effectiveness of interventions to reduce maternal morbidity and mortality in Mexico. PLoS ONE 2: e750.
34. Hu D, Grossman D, Levin C, Blanchard K, Goldie SJ (2009) Cost-effectiveness analysis of alternative first-trimester pregnancy termination strategies in Mexico City. BJOG 116: 768-779.
35. Jowett M (2000) Safe Motherhood interventions in low-income countries: an economic justification and evidence of cost effectiveness. Health Policy 53: 201-228.
36. Bhutta ZA, Ali S, Cousens S, Ali TM, Haider BA, et al. (2008) Alma-Ata: Rebirth and Revision 6 Interventions to address maternal, newborn, and child survival: what difference can integrated primary health care strategies make? Lancet 372: 972-989.
37. Bartlett LA, Berg CJ, Shulman HB, Zane SB, Green CA, et al. (2004) Risk factors for legal induced abortion-related mortality in the United States. Obstet Gynecol 103: 729-737.
38. Fernandez MM, Coeytaux F, de Leon RGP, Harrison DL (2009) Assessing the global availability of misoprostol. International Journal of Gynecology & Obstetrics 105: 180-186.
39. World Health Organisation, Maternal Mortality in 2005: Estimates developed by WHO, UNICEF, UNFPA and The World Bank. http://www.who.int/making_pregnancy_safer/documents/9789241596213/en/ind ex.html accessed 24th July 2008.
40. National Bureau of Statistics (NBS) [Tanzania] and ORC Macro (2005) Tanzania Demographic and Health Survey 2004-05. Dar es Salaam, Tanzania: National Bureau of Statistics and ORC Macro, Available: http://www.measuredhs.com/pubs/pub_details.cfm?ID=566 Accessed 2009 May 12.
41. Harries J, Stinson K, Orner P (2009) Health care providers' attitudes towards termination of pregnancy: a qualitative study in South Africa. BMC Public Health 9: 296.
42. Harrison A, Montgomery ET, Lurie M, Wilkinson D (2000) Barriers to implementing South Africa's Termination of Pregnancy Act in rural KwaZulu/ Natal. Health Policy Plan 15: 424-431.
43. Turner KL, Hyman AG, Gabriel MC (2008) Clarifying values and transforming attitudes to improve access to second trimester abortion. Reprod Health Matters 16: 108-116.
44. Morhe ES, Morhe RA, Danso KA (2007) Attitudes of doctors toward establishing safe abortion units in Ghana. Int J Gynaecol Obstet 98: 70-74.
45. Lovold A, Stanton C, Armbruster D (2008) How to avoid iatrogenic morbidity and mortality while increasing availability of oxytocin and misoprostol for PPH prevention? Int J Gynaecol Obstet 103: 276-282.
46. World Health Organisation Mother-Baby Package (1994) Implementing safe motherhood in countries. WHO/FSE/MSM/94.11. Geneva. Available: http://whqlibdoc.who.int/hq/1994/WHO_FHE_MSM_94.11_Rev.1.pdf Accessed 2009 September 12.
47. Levin C, Grossman D, Berdichevsky K, Diaz C, Aracena B, et al. (2009) Exploring the costs and economic consequences of unsafe abortion in Mexico City before legalisation. Reprod Health Matters 17: 120-132.
48. Ronsmans C, Graham WJ (2006) Maternal mortality: who, when, where, and why. Lancet 368: 1189-1200.
49. Berer M (2009) Provision of abortion by mid-level providers: international policy, practice and perspectives. Bull World Health Organ 87: 58-63.
50. Gebreselassie H, Fetters T (2002) Responding to unsafe abortion in Ethiopia: A facility-based assessment of postabortion care services in public-health sector facilities in Ethiopia. Available: http://www.ipas.org/Publications/asset_upload_file965_2470.pdf Accessed 2009 October 20.
51. United Nations Population Division (No date) Abortion policies: a global review. United Republic of Tanzania. Available: http://www.un.org/esa/population/publications/abortion/doc/tanzania.doc Accessed 2007 August 10.
52. Central Statistical Agency [Ethiopia] and ORC Macro (2006) Ethiopia Demographic and Health Survey 2005. Addis Ababa, Ethiopia and Calverton, Maryland USA. Available: http://www.measuredhs.com/pubs/pdf/FR179/FR179.pdf Accessed 2009 May 12.
53. Billings DL (2004) Misoprostol alone for early medical abortion in a Latin American clinic setting. Reprod Health Matters 12: 57-64.
54. Jain JK, Dutton C, Harwood B, Meckstroth KR, Mishell DR, Jr. (2002) A prospective randomized, double-blinded, placebo-controlled trial comparing mifepristone and vaginal misoprostol to vaginal misoprostol alone for elective termination of early pregnancy. Hum Reprod 17: 1477-1482.
55. Grimes DA (2005) Risks of mifepristone abortion in context. Contraception 71: 161.
56. Gebreselassie H, Fetters T, Singh S, Abdella A, Gebrehiwot Y, et al. (2010) Caring for women with abortion complications in Ethiopia: national estimates and future implications. Int Perspect Sex Reprod Health 36: 6-15.
57. Bankole A, Sedgh G, Oye-Adeniran BA, Adewole IF, Hussain R, et al. (2008) Abortion-seeking behaviour among Nigerian women. J Biosoc Sci 40: 247-268.
58. United Nations, Statistics, Demographic Yearbook. Available: https://www.cia.gov/library/publications/the-world-factbook/ Accessed 2009 September 12.